Towards Healthcare
Oral GLP-1 Market Trends and Companies

Oral GLP-1 Market Thrives Amid Global Obesity Epidemic

The rising prevalence of Type 2 diabetes has driven the growth of the market in the near future. North America led the global market owing to its advanced healthcare infrastructure in the region.

Content

  • Last Updated: 22 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The Oral GLP-1 market expected to generate massive revenue by 2034, driven by rising demand, innovation, and strong investments.

North America is leading the Oral GLP-1 market share by 46% due to the growing prevalence of diabetes, rapid adoption of innovative therapies, and presence of major key players.

The Oral GLP-1 market includes five segments including by drug type, by molecule, by distribution channel, by end user, and by region.

Key trends include the rising preference for oral therapies, expansion into obesity management, pharmaceutical innovation and new launches, and growing awareness and healthcare programs, among others.

American Diabetes Association, Diabetic Association of India, Food and Drug Administration, DiabetesIndia, clinicaltrials.gov, International Diabetes Federation, WHO, JAMA, World Diabetes Foundation, and GOV.UK, among others.
Any Questions